Hormonal Aromatase InhibitorFDA-approved medicinePrescription drug

Anastrozole

Arimidex

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

0.25-0.5mg – 0.25-0.5 mg Oral 2-3x per week

Hormone ModulatorEstrogen Management

Anastrozole (brand name Arimidex) is a potent, selective, non-steroidal aromatase inhibitor (AI) that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens to estrogens. It was originally developed for the treatment of estrogen receptor-positive breast cancer in postmenopausal women.

Quick Start

Route

Oral

Start low

0.25-0.5mg Oral

Frequency

2-3x per week

Timing

Can be taken with or without food

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

0.25-0.5mg · Oral · 2-3x per week

conservative starter

0.25-0.5mg

2-3x per week

Intermediate

Estrogen Management (AI)

0.25-0.5 mg · Oral · 2x Weekly

human clinical trial · Mauras et al. 2000 (J Clin Endocrinol Metab)

Dose strictly based on bloodwork (Estradiol ultrasensitive). Do not preemptively take AIs without confirmed symptoms or labs.

0.25-0.5 mg

2x Weekly

◆

How it works

Anastrozole works by selectively and reversibly binding to the aromatase enzyme (CYP19A1), blocking the conversion of testosterone and androstenedione into estradiol and estrone. Unlike SERMs (which block estrogen receptors), anastrozole reduces total circulating estrogen levels. This mechanism preserves the HPG axis feedback loop - lowered estrogen can increase LH/FSH output in some contexts, though this effect is secondary to its primary use as an estrogen reducer alongside exogenous testosterone.

What to expect

Early

Days 1–7

Days 1-7: Anastrozole reaches steady state quickly due to long half-life. Some reduction in water retention and bloating may be noticed. E2 levels begin declining.

Evidence

HumanStrong

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Primary safety: long-term ATAC follow-up quantified treatment-related and serious adverse events.

At median follow-up of 68 months (range 1-93), treatment-related adverse events occurred significantly less often with anastrozole than with tamoxifen (1884 [61%] vs 2117 [68%]; p<0.0001), as did treatment-related serious adverse events (146 [5%] vs 277 [9%]; p<0.0001) and adverse events leading to withdrawal (344 [11%] vs 442 [14%]; p=0.0002).

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. The Lancet. Oncology · 2006 · PMID 16887480

Evidence scope. Human; postmenopausal women with early-stage breast cancer; adjuvant anastrozole vs tamoxifen; median 68-month follow-up (ATAC trial).

Mechanism/class: anastrozole is a third-generation aromatase inhibitor.

Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer.

Anastrozole. Expert opinion on drug safety · 2010 · PMID 20923259

Evidence scope. Narrative review; adjuvant hormone-receptor-positive breast-cancer context specifically.

Specific safety concern: aromatase inhibitors have reported vertebral deformities, lower HDL, and erythrocytosis in pediatric use.

Although aromatase inhibitors appear effective in increasing adult height of boys with short stature and/or pubertal delay, safety concerns, including vertebral deformities, a decrease in serum HDL cholesterol levels and increase of erythrocytosis, are reasons for caution.

Aromatase inhibitors in pediatrics. Nature reviews. Endocrinology · 2011 · PMID 22024975

Evidence scope. Human, pediatric (boys with short stature/pubertal delay), off-label use; class-wide (letrozole + anastrozole) safety signal, not decomposed by individual agent in the abstract.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 0.25-0.5 mg orally 2-3x/week. The checked human abstracts primarily use approved 1 mg/day oncology regimens or class-level dosing; none verified the card schedule.

The honest take

◆

All men on TRT need an AI

Not supported

False. Many men on TRT manage estradiol without an AI. Modern TRT practice favors more frequent, lower-dose injections to minimize aromatization rather than defaulting to AI use. AIs should be reserved for men with confirmed elevated E2 and symptoms.

Anastrozole can boost testosterone naturally

Partly true

Partially true in hypogonadal men not on TRT - reduced E2 decreases negative feedback on the HPG axis, increasing LH and endogenous testosterone. However, this effect is modest and not a substitute for TRT in truly hypogonadal men.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

DHEADHEA converts to androgens and estrogens - AI can manage resulting estradiol if needed

GnRH (Gonadorelin)No pharmacological conflict - different mechanisms for HPG axis support

PregnenoloneNo direct interaction - pregnenolone is upstream in steroid pathway

Nandrolone DecanoateAI manages estradiol from concurrent testosterone use in stacked protocols

Keep separate

LetrozoleStacking two aromatase inhibitors risks severe estradiol crash - use one AI only

TamoxifenAnastrozole and tamoxifen have a pharmacokinetic interaction - tamoxifen reduces anastrozole plasma levels by ~27%

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Joint pain and stiffness (most common complaint in men)
Fatigue and low energy if E2 over-suppressed
Mood changes, irritability, or flat affect
Headache
Dry skin

Less common & notes

Over-suppression of estradiol can lead to decreased bone mineral density over time, unfavorable lipid changes (increased LDL), and sexual dysfunction.
Estradiol is important for male cardiovascular and bone health - never crash E2 to undetectable levels.

Pharmacokinetics

Illustrative plasma concentration · 8 d

Half-life

~50 hours

Peak · Tmax

~2 hours

Elimination

~10 days

Bioavailability

~100%

Oral

Duration of action

3-5 days

Sustained estradiol suppression per dose

Clearance

Hepatic (CYP3A4 and CYP2C8 N-dealkylation, glucuronidation); renal excretion of metabolites

Storage. Store at room temperature (20-25C). Protect from moisture and light. Oral tablet or capsule - no reconstitution needed. Compounded liquid formulations should be stored per pharmacy instructions.

Regulatory status

FDA-approved (Arimidex) for adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women. Use in men for estradiol management during TRT is off-label but widely practiced. Available by prescription. Generic versions widely available.

Put it to work

Calculate, log & track

Open Anastrozole straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Anastrozole in the app →

Go deeper

The guide & community

The complete Anastrozole walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community